Therapeutic antibodies and anaphylaxis: Anaphylaxis among other acute reactions, role of anti-glycan antibodies and practical consequences for patients
Second Charles Richet and Jules Héricourt workshop
Cytokine-release syndromes frequently occur write my paper for me during the first infusion of therapeutic antibodies, particularly in cancer. However, these sometimes serious side-effects can be difficult to distinguish from “anaphylactoid” reactions. The TGN1412 phase I trial and the post-approval surveillance of cetuximab have now revealed two new entities: “cytokine storm”, and anaphylaxis without any pre-sensitization phase, respectively. The fact that the latter is due to pre-formed anti-alphaGal IgE antibodies highlights the issue of non-human glycosylation of biologics and their antigenicity and immunogenicity. These new findings should also be integrated into clinical practice, raising questions about custom writing the management of patients taking cetuximab.
This post is also available in: French